Roche's Neuroscience Franchise Gets Lift From Huntington's Breakthrough
Roche is aiming to bolster its future neuroscience franchise with another potential breakthrough product in neurology to add to its clinical-stage efforts in Alzheimer's disease, and its success in developing the first therapy for primary progressive multiple sclerosis, Ocrevus.
You may also be interested in...
What Does 2018 Hold For Biopharma?
From ongoing progress in IO to revolutions in AI, and from pricing headaches to new therapies for migraine: Scrip has gleaned from experts and industry executives their expectations and predictions for 2018's hot topics. Here is our digest.
Roche Delivers Strong Quarter On Ocrevus Launch, Pipeline Promise
Roche's strong first quarter and promising array of innovative medicines left investors wondering why it didn't also lift its financial guidance for the year.
Teva’s Austedo Positioned To Compete With A Generic Rival
FDA approved Teva’s Austedo (deutetrabenazine) for chorea associated with Huntington’s disease, with a warning on depression and suicidality similar to generic Xenazine, but other parts of the labeling points to advantages.